mirikizumab Omvoh
Selected indexed studies
- Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. (Lancet, 2024) [PMID:39581202]
- Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. (N Engl J Med, 2023) [PMID:37379135]
- ** (, 2024) [PMID:38588359]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (2024) pubmed
- Mirikizumab: First Approval. (2023) pubmed
- Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. (2024) pubmed
- Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. (2023) pubmed
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (2020) pubmed
- PMID:38588359 (2024) pubmed
- Mirikizumab (Omvoh) for ulcerative colitis. (2024) pubmed
- PMID:38301063 (2023) pubmed
- Mirikizumab (Omvoh™) for ulcerative colitis. (2024) pubmed
- Mirikizumab (Omvoh) - an IL-23 antagonist for Crohn's disease. (2025) pubmed